Galectin Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Galectin Therapeutics
GALT Stock  USD 4.05  0.11  2.64%   
Analyzing historical trends in various income statement and balance sheet accounts from Galectin Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Galectin Therapeutics' valuation are summarized below:
Market Capitalization
261.1 M
Earnings Share
(0.59)
There are currently one hundred twenty fundamental trends for Galectin Therapeutics that can be evaluated and compared over time across competitors. All traders should confirm Galectin Therapeutics' regular fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 114.5 M in 2026. Enterprise Value is likely to gain to about 104.5 M in 2026
Check Galectin Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galectin Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 33 K, Interest Expense of 6.7 M or Selling General Administrative of 5.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0012 or Days Sales Outstanding of 0.0. Galectin financial statements analysis is a perfect complement when working with Galectin Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Galectin Stock
Check out the analysis of Galectin Therapeutics Correlation against competitors.
For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.

Galectin Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets15.1 M20.1 M19.7 M
Slightly volatile
Short and Long Term Debt Total128.3 M122.2 M29.3 M
Slightly volatile
Other Current Liabilities10.4 M9.9 M4.3 M
Slightly volatile
Total Current Liabilities42.8 M40.7 M10.8 M
Slightly volatile
Accounts Payable6.8 M6.5 M2.3 M
Slightly volatile
Cash13.9 M17.4 M18.4 M
Slightly volatile
Non Current Assets Total234.7 K279.4 K183.7 K
Slightly volatile
Cash And Short Term Investments14.1 M17.4 M18.4 M
Slightly volatile
Common Stock Total Equity35.5 K64.4 K38.4 K
Slightly volatile
Common Stock Shares Outstanding75.2 M71.7 M40.7 M
Slightly volatile
Liabilities And Stockholders Equity15.1 M20.1 M19.7 M
Slightly volatile
Other Stockholder Equity357.7 M340.6 M202.1 M
Slightly volatile
Total Liabilities145.6 M138.6 M36 M
Slightly volatile
Total Current Assets14.8 M19.8 M19.5 M
Slightly volatile
Short Term Debt25.5 M24.3 M4.2 M
Slightly volatile
Common Stock40.4 K71.3 K40.1 K
Slightly volatile
Other Current Assets2.6 M2.5 M1.2 M
Slightly volatile
Property Plant And Equipment Gross134.2 K85.1 K191.4 K
Pretty Stable
Other Liabilities56.4 K59.4 K68.2 K
Slightly volatile
Preferred Stock Total Equity450.6 K474.3 K2.5 M
Slightly volatile
Net Receivables187.2 K210.6 K229.9 K
Slightly volatile
Warrants2.9 M1.6 M3.6 M
Slightly volatile
Capital Surpluse200.2 M301.2 M194.9 M
Slightly volatile
Capital Stock2.6 M2.1 M5.8 M
Slightly volatile
Capital Lease Obligations26.1 K17.1 K34.7 K
Slightly volatile
Short and Long Term Debt16.9 M19 M20.7 M
Slightly volatile

Galectin Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative5.3 M6.7 M5.8 M
Slightly volatile
Other Operating Expenses51.2 M48.8 M23.8 M
Slightly volatile
Research Development44.2 M42.1 M17.9 M
Slightly volatile
Total Operating Expenses51.2 M48.8 M23.8 M
Slightly volatile
Preferred Stock And Other Adjustments117.1 K123.3 K564 K
Slightly volatile
Interest Income408.1 K388.7 K123 K
Slightly volatile
Selling And Marketing Expenses35.2 K39.6 K43.2 K
Slightly volatile

Galectin Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities37.7 M35.9 M19.9 M
Slightly volatile
End Period Cash Flow13.9 M17.4 M18.4 M
Slightly volatile
Begin Period Cash Flow31 M29.5 M19.6 M
Slightly volatile
Depreciation37.4 K33.3 K29.4 K
Very volatile
Stock Based Compensation2 M2.8 M2.4 M
Very volatile
Change To Netincome2.3 M2.4 M3 M
Slightly volatile
Net Borrowings21.7 M27 M28.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Dividend Yield0.00120.00130.009
Slightly volatile
Average Payables157 K211 K224 K
Very volatile
Capex To Depreciation0.640.480.4885
Slightly volatile
Payables Turnover0.00710.00750.0242
Slightly volatile
Cash Per Share0.270.280.5116
Slightly volatile
Days Payables Outstanding52.7 K50.2 K30.7 K
Slightly volatile
Income Quality0.911.020.7878
Slightly volatile
Intangibles To Total Assets1.0E-41.0E-40.0033
Slightly volatile
Current Ratio0.420.445.4454
Slightly volatile
Capex Per Share3.0E-43.0E-46.0E-4
Slightly volatile
Interest Debt Per Share1.71.610.4466
Slightly volatile
Debt To Assets5.745.471.3384
Slightly volatile
Days Of Payables Outstanding52.7 K50.2 K27.1 K
Slightly volatile
Ebt Per Ebit0.811.01.0113
Slightly volatile
Total Debt To Capitalization31.6230.126.3617
Slightly volatile
Quick Ratio0.420.445.4454
Slightly volatile
Net Income Per E B T1.461.641.7878
Slightly volatile
Cash Ratio0.470.495.2831
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.151.023
Slightly volatile
Debt Ratio5.745.471.3384
Slightly volatile

Galectin Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap114.5 M109 M84.9 M
Slightly volatile
Enterprise Value104.5 M99.5 M70.1 M
Slightly volatile

Galectin Fundamental Market Drivers

Galectin Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Galectin Therapeutics Financial Statements

Galectin Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Galectin Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Galectin Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Galectin Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-6 M-5.7 M
Cost Of Revenue33.3 K19.3 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Galectin Stock Analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY